The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review

被引:6
|
作者
Zi, Yingxin [1 ,2 ]
Deng, Yu [1 ,2 ]
Ji, Meiqi [1 ,2 ]
Qin, Yali [1 ,2 ]
Nong, Luqi [1 ,2 ]
Liu, Ziqiang [1 ,2 ]
Jin, Ming [2 ]
机构
[1] Beijing Univ Chinese Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Ophthalmol, 2 Yinghua Donglu, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
allergic conjunctivitis; olopatadine hydrochloride eye drops; protocol; systematic review; RHINITIS;
D O I
10.1097/MD.0000000000018618
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Allergic conjunctivitis (AC) is a multifactorial and common type of ocular surface disease that affects many people. The quality of life for AC patients can be significantly decreased caused by symptoms of ocular itching, swelling, redness, and tearing. Topical antihistaminics, mast cell stabilizers, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids have been widely used to treat AC. Many clinical trials have indicated that olopatadine hydrochloride eye drops can provide quick relief of symptoms and signs. The purpose of this review is to evaluate systematically the effectiveness of olopatadine hydrochloride eye drops for treating AC.Methods:A systematic review of all of the randomized controlled trials on the effectiveness and safety of olopatadine hydrochloride eye drops for AC will be conducted. We will search PubMed, Web of Science (WOS), EMBASE (OVID), the Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal database (VIP), Wanfang Database, and CBM, from the database inception date to October 31, 2019. There are no language or publication status restrictions. Registers of clinical trials, potential gray literature, reference lists of studies, and conference abstracts will also be searched. Two reviewers will independently read the articles, extract the data information, and assess the quality of the studies. Data will be synthesized by a heterogeneity test. The primary outcomes include the main symptom and sign scores before and after treatment, the eye redness index, the presence of eosinophils in the conjunctival scraping. Quality of life, the total treatment efficacy, and safety will be evaluated as the secondary outcomes. RevMan V.5.3 software will be used for the meta-analysis.Results:The study will provide an objective and normative systematic review to evaluate the effectiveness and safety of olopatadine hydrochloride eye drops for the treatment of AC.Conclusion:Our review will provide useful information to judge whether olopatadine hydrochloride eye drops is an effective intervention for patients with AC.Ethics and dissemination:It is not necessary to obtain ethical approval as participants are not involved patients. The protocol and results will be published in a peer-reviewed journal. The systematic review will also be disseminated electronically and in print to help guide health care practice and policy.Prospero registration number:PROSPERO CRD42019132232.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort
    Michael Ganz
    Elizabeth Koll
    Jean Gausche
    Paul Detjen
    Nicholas Orfan
    Advances in Therapy, 2003, 20 : 79 - 91
  • [32] Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
    Torkildsen, Gail
    Narvekar, Abhijit
    Bergmann, Mark
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1703 - 1713
  • [33] UHPLC Study on the Degradation Profiles of Olopatadine Hydrochloride in Eye Drops Subjected to Heat and Filtration Methods of Sterilisation
    L. Munjas Jurkic
    M. Buratovic
    I. Valentic
    D. Stanfel
    Chromatographia, 2014, 77 : 1067 - 1080
  • [34] Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye
    Mah, F. S.
    O'Brien, T.
    Kim, T.
    Torkildsen, G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (02) : 441 - 447
  • [35] UHPLC Study on the Degradation Profiles of Olopatadine Hydrochloride in Eye Drops Subjected to Heat and Filtration Methods of Sterilisation
    Jurkic, L. Munjas
    Buratovic, M.
    Valentic, I.
    Stanfel, D.
    CHROMATOGRAPHIA, 2014, 77 (15-16) : 1067 - 1080
  • [36] Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort
    Ganz, M
    Koll, E
    Gausche, J
    Detjen, P
    Orfan, N
    ADVANCES IN THERAPY, 2003, 20 (02) : 79 - 91
  • [37] The effectiveness and safety of moxibustion for dry eye Protocol for a systematic review
    Zi, Yingxin
    Ji, Meiqi
    Deng, Yu
    Qin, Yali
    Wang, Rui
    Meng, Huan
    Jin, Ming
    MEDICINE, 2019, 98 (15)
  • [38] Prevalence of Comorbidity between Dry Eye and Allergic Conjunctivitis: A Systematic Review and Meta-Analysis
    Akasaki, Yasutsugu
    Inomata, Takenori
    Sung, Jaemyoung
    Nakamura, Masahiro
    Kitazawa, Koji
    Shih, Kendrick Co
    Adachi, Takeya
    Okumura, Yuichi
    Fujio, Kenta
    Nagino, Ken
    Midorikawa-Inomata, Akie
    Kuwahara, Mizu
    Hirosawa, Kunihiko
    Huang, Tianxiang
    Morooka, Yuki
    Shokirova, Hurramhon
    Eguchi, Atsuko
    Murakami, Akira
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [39] TO EVALUATE EFFICACY OF CYCLOSPORINE 0.1% EYE DROPS AS MAINTENANCE THERAPY IN PATIENTS OF ALLERGIC CONJUNCTIVITIS
    Raina, Bhavani
    Kai, Sanjay
    Sharma, Pallavi
    Bharti, Anuradha
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2018, 7 (46): : 5021 - 5024
  • [40] Comparative efficacy of caffeic acid phenethyl ester (CAPE), olopatadine hydrochloride, and dexamethasone sodium phosphate in experimental allergic conjunctivitis
    Aydin, Erdinc
    Demir, Helin Deniz
    Ozyurt, Huseyin
    Erkorkmaz, Unal
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2010, 40 (04) : 605 - 612